Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT01439009

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01439009
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01439009. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2014-03 (actual). Results posted on 2019-10-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
Condition
Heart Failure
Intervention (Drug)
Tolvaptan
Intervention (Drug)
Placebo of tolvaptan
Lead sponsor
Otsuka Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01439009
Content hash
2330b29b7d42de85b12bf211dc04d1d6b78eb9575a90f8c295beb64ed3e3b322